Sarepta Therapeutics (SRPT) Vyondys 53 Granted Accelerated FDA Approval to Treat DMD
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Sarepta Therapeutics (SRPT) PT Raised to $190 at Credit Suisse
December 13, 2019 7:44 AM ESTCredit Suisse analyst Martin Auster raised the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $190.00 (from $185.00) while maintaining an Outperform rating after the FDA approved Vyondys 53.
The company plans to price the drug at parity with Exondys 51 or >$600,000 for a... MoreSarepta Therapeutics (SRPT) PT Raised to $215 at RBC Capital; 'Vynodys Approval A Big Win'
December 13, 2019 6:19 AM ESTRBC Capital analyst Brian Abrahams raised the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $215.00 (from $200.00) while maintaining an Outperform rating following approval of Vyondys 53/golodirsen.
The analyst commented, "We view tonight's approval of Vyondys 53/golodirsen as a significant win for SRPT,... More
Sarepta Therapeutics (SRPT) halted, news pending
December 12, 2019 5:52 PM ESTSarepta Therapeutics (NASDAQ: SRPT) halted, news pending
... More